BOSTON SCIENTIFIC CORP
SEC data synchronized Nov 8, 2026 16:31 UTC
Interactive Stock Price Chart — BSX
Powered by TradingViewInteractive stock chart provided by TradingView. Market data may be delayed or unavailable. Stock prices are separate from SEC-reported financial data.
Financial highlights
Latest qualifying annual SEC observations · USDAbout BOSTON SCIENTIFIC CORP
Business Overview
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties. As a medical technology leader for more than 45 years, we have advanced the practice of less-invasive medicine by helping physicians and other medical professionals diagnose and treat a wide range of diseases and medical conditions and improve patients’ quality of life by providing alternatives to surgery and other medical procedures that are typically traumatic to the body.
Business information sourced from SEC annual filing filed Feb 17, 2026. Business descriptions reflect the cited filing and may not describe subsequent changes.
Company identification is based on SEC registration information. Financial figures are sourced from SEC filings.
Company Details
- Registered name
- BOSTON SCIENTIFIC CORP
- Ticker symbol
- BSX
- CIK
- 0000885725
- Exchange
- NYSE
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC SIC code
- 3841
- Fiscal year end (MMDD)
- 1231
- Last SEC synchronization
- Nov 8, 2026 16:31 UTC
Company contact information is drawn from SEC submissions, where reported, and may not reflect current operating locations. Official website, business descriptions and executive details require separate verification.
Historical financial performance
USD billions · Annual SEC observations · Choose a metric
Each metric uses a consistent SEC accounting concept when available. Fiscal year-end dates may differ across metrics. Negative values are displayed with a minus sign.
Annual financial history
USD · Exact fiscal period ends| Period ended | Revenue | Net income | Operating income | Assets | Liabilities | Cash | Operating cash flow | Net margin |
|---|---|---|---|---|---|---|---|---|
| Dec. 31, 2025 | $20.07B | — | $3.61B | $43.67B | — | $1.96B | $4.53B | — |
| Dec. 31, 2024 | $16.75B | — | $2.60B | $39.40B | — | $414.00M | $3.44B | — |
| Dec. 31, 2023 | $14.24B | — | $2.34B | $35.14B | — | $865.00M | $2.50B | — |
| Dec. 31, 2022 | $12.68B | — | $1.65B | $32.47B | — | $928.00M | $1.53B | — |
| Dec. 31, 2021 | $11.89B | — | $1.20B | $32.23B | — | $1.92B | $1.87B | — |
| Dec. 31, 2020 | $9.91B | — | −$80.00M | $30.78B | — | $1.73B | $1.51B | — |
| Dec. 31, 2019 | $10.74B | — | $1.52B | $30.56B | — | $217.00M | $1.84B | — |
| Dec. 31, 2018 | $9.82B | — | $1.51B | $21.00B | — | $146.00M | $310.00M | — |
A dash indicates unavailable or nonmatching period data. Figures are SEC observations, not estimates.
Latest SEC filings
Browse filings →| Form | Filed | Report period | Official source |
|---|---|---|---|
| 10-K | Feb. 17, 2026 | Dec. 31, 2025 | View SEC filing ↗ |
| 10-K | Feb. 18, 2025 | Dec. 31, 2024 | View SEC filing ↗ |
| 10-K | Feb. 20, 2024 | Dec. 31, 2023 | View SEC filing ↗ |
| 10-K | Feb. 23, 2023 | Dec. 31, 2022 | View SEC filing ↗ |
| 10-K | Feb. 23, 2022 | Dec. 31, 2021 | View SEC filing ↗ |
| 10-K | Feb. 23, 2021 | Dec. 31, 2020 | View SEC filing ↗ |
Financial data is provided for informational purposes, not investment advice. Observations may include restatements; review original SEC filings before making decisions.